MIRM

Mirum Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website mirumpharma.com
Employees(FY) 249
ISIN US6047491013

Performance

+3.33%

+10.72%

+4.45%

+81.51%

+48.0%

YTD

+36.11%

Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Advanced Technical Analysis

Technical Analysis of MIRM 2024-11-20

The stock exhibits a strong bullish sentiment, highlighted by a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 78 further supports this positive outlook. Although the Oscillators Score of 60 suggests a neutral stance, the overall indicators point towards a favorable market environment for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MIRM

Stock Rank

Recent News & Updates

2024-11-15 08:20
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results(Simply Wall St.)
2024-11-14 08:00
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting(Business Wire)
2024-11-14 05:18
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-11-13 19:00
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting(Businesswire)
2024-11-13 02:09
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...(GuruFocus.com)
2024-11-12 11:44
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised(Zacks)
2024-11-12 09:15
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-11-12 08:23
Mirum Pharmaceuticals' Q3 Loss Narrows, Revenue Rises(MT Newswires)
2024-11-12 08:00
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update(Business Wire)
2024-11-11 19:00
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update(Businesswire)
2024-11-08 18:30
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-11-08 05:30
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-07 16:30
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences(Business Wire)
2024-11-07 03:30
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences(Businesswire)
2024-11-06 13:02
High Growth Tech Stocks In The United States To Watch(Simply Wall St.)
2024-11-04 16:30
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024(Business Wire)
2024-11-04 03:30
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024(Businesswire)
2024-10-31 10:02
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know(Zacks)
2024-10-31 08:30
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting(Business Wire)
2024-10-30 20:30
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting(Businesswire)
2024-10-23 08:49
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth(Insider Monkey)
2024-10-10 19:30
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-10-10 09:25
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus(MT Newswires)
2024-10-10 08:30
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis(Business Wire)
2024-10-10 07:30
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-10-09 20:30
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis(Businesswire)
2024-10-09 17:18
Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ...(GuruFocus.com)
2024-10-03 10:04
Exploring High Growth Tech Stocks In The US October 2024(Simply Wall St.)
2024-09-10 20:45
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-09-10 08:45
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.